Probiotics and the Neurodevelopment in the Premature Infant <32 Weeks Gestational Age and <1500g
Infant, Newborn, Diseases, Infant Development
About this trial
This is an interventional treatment trial for Infant, Newborn, Diseases focused on measuring Probiotics, Bifidobacterium bifidum, Lactobacillus acidophilus, Neurodevelopment, Prematurity, Late-onset sepsis
Eligibility Criteria
Inclusion Criteria: Premature infants under 32 weeks gestational age and less than 1500g birthweight. Born at BCNatal Hospital Clínic between years 2014-2019. Exclusion Criteria: All neonates presenting with suspected congenital anomalies, inborn errors of metabolism, or genetic defects were excluded. Infants with a suspected syndrome, or who have suffered events beyond the neonatal period, not related to prematurity, that could entail impairment in neurodevelopment (severe cranioencephalic trauma, oncological process, meningitis, or exposure to toxic substances)
Sites / Locations
- Neonataology Service, BCNatal Hospital Clinic Seu Maternitat
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Bifidobacterium bifidum NCDO 2203 and Lactobacillus acidophilus NCDO 1748
Control
Daily dose of 6x109 UFC Infloran® -Berne, Switzerland- (Bifidobacterium bifidum NCDO 2203 and Lactobacillus acidophilus NCDO 1748) from 7 days of life until reaching a postmenstrual age of 34 weeks or discharge
Untreated control group